Replies to post #26949 on SLEEKSCAPE'S 2022 CANNABIS & MARIJUANA MANIA GRAND

[Slider25]

Here is Bolton's role, he is actually a very high level and works with FDA relations:

Mark Bolton serves as Senior Director of US Public Policy & Senior Counsel for GW Pharmaceuticals. In that capacity, Mark oversees all federal and state public policy issues for GW, including the company’s interactions with Congress, the FDA and the DEA

So, I would think that he may have an inside track on the direction the FDA is going, enforcement discretion. He mentions the selling of CBD mass market, and the FDA would require effective QC. Kind of sounded like a done deal and I don't think he would have said that if that was not the direction the FDA was going.

This is minor compared to the Gottlieb clues that you provided in depth analysis for which boosted the confidence levels for approval. However, it's positive to see a GW Exec mention it. They have a bunch of active and new trials, I am curious to see if they involve other compounds with CBD. I'll see if I can come across the transcript for his speech.

Bolton said that state policies should encourage development of FDA-approved cannabis-derived medicines for serious and life-threatening diseases but that consumers need strong quality control over products to be sold in a mass-market setting without physician oversight. Bolton added that he is certain FDA will take this approach